Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection.

Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection.

<h4>Introduction</h4>Achieving functional cure of chronic HBV infection (Hepatitis B surface antigen [HBsAg] clearance, eventually followed by acquisition of anti-hepatitis B surface antigen [Anti-HBs]) in individuals with HIV and HBV infections is a rare event. In this setting, factors...

Full description

Bibliographic Details
Main Authors: Pierre Gantner, Laurent Cotte, Clotilde Allavena, Firouzé Bani-Sadr, Thomas Huleux, Claudine Duvivier, Marc-Antoine Valantin, Christine Jacomet, Véronique Joly, Antoine Chéret, Pascal Pugliese, Pierre Delobel, André Cabié, David Rey, Dat’AIDS Study Group
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0215464

Internet

https://doi.org/10.1371/journal.pone.0215464

Similar Items